Adma Biologics Inc Einnahmen
Was ist das Einnahmen von Adma Biologics Inc?
Einnahmen von Adma Biologics Inc ist 58.69%
Was ist die Definition von Einnahmen?
Das jährliche Umsatzwachstum der letzten 3 Jahre ist das durchschnittliche Umsatzwachstum der letzten 3 Jahre von einem Jahr zum nächsten.
The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.
Einnahmen von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Adma Biologics Inc
Was macht Adma Biologics Inc?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Unternehmen mit einnahmen ähnlich Adma Biologics Inc
- Adani Enterprises hat Einnahmen von 58.53%
- Duncan Engineering hat Einnahmen von 58.58%
- Rekor Systems Inc hat Einnahmen von 58.63%
- Ratnamani Metals & Tubes hat Einnahmen von 58.67%
- NRG hat Einnahmen von 58.68%
- NRG hat Einnahmen von 58.68%
- Adma Biologics Inc hat Einnahmen von 58.69%
- Solar Alliance hat Einnahmen von 58.71%
- RYB Education Inc hat Einnahmen von 58.73%
- Xvivo Perfusion AB (publ) hat Einnahmen von 58.78%
- Perimeter Medical Imaging AI hat Einnahmen von 58.79%
- Perimeter Medical Imaging AI hat Einnahmen von 58.79%
- New World Resource hat Einnahmen von 58.79%